Cyclerion Therapeutics, Inc.

NasdaqCM:CYCN Stock Report

Market Cap: US$7.7m

Cyclerion Therapeutics Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureno data
CEO ownershipn/a
Management average tenureno data
Board average tenure3.3yrs

Recent management updates

Recent updates

Cyclerion stock tanks 32% on workforce reduction, clinical development refocus

Oct 06

We're Keeping An Eye On Cyclerion Therapeutics' (NASDAQ:CYCN) Cash Burn Rate

Aug 09
We're Keeping An Eye On Cyclerion Therapeutics' (NASDAQ:CYCN) Cash Burn Rate

We're Keeping An Eye On Cyclerion Therapeutics' (NASDAQ:CYCN) Cash Burn Rate

Mar 03
We're Keeping An Eye On Cyclerion Therapeutics' (NASDAQ:CYCN) Cash Burn Rate

Cyclerion Therapeutics: Distressed Spinoff Developing New Medicines For CNS Disorders

Oct 26

Cyclerion Therapeutics: Insiders Buying With No Clinical Data Due Until YE 2021

Jun 21

Cyclerion climbs on a series of insider purchases

Jun 08

Cyclerion updates on clinical trial progress at webinar

Apr 28

Who Has Been Buying Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) Shares?

Mar 09
Who Has Been Buying Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) Shares?

What Kind Of Shareholders Hold The Majority In Cyclerion Therapeutics, Inc.'s (NASDAQ:CYCN) Shares?

Jan 28
What Kind Of Shareholders Hold The Majority In Cyclerion Therapeutics, Inc.'s (NASDAQ:CYCN) Shares?

Cyclerion Therapeutics +10.5% after prelim reports

Jan 13

Cyclerion Therapeutics announces promotions

Dec 21

Can You Imagine How Cyclerion Therapeutics' (NASDAQ:CYCN) Shareholders Feel About The 40% Share Price Increase?

Dec 20
Can You Imagine How Cyclerion Therapeutics' (NASDAQ:CYCN) Shareholders Feel About The 40% Share Price Increase?

Cyclerion Therapeutics reports Q3 results

Nov 05

CEO

Cyclerion Therapeutics has no CEO, or we have no data on them.


Board Members

NamePositionTenureCompensationOwnership
Terrance McGuire
Independent Director5yrsUS$59.03k0.23%
$ 17.9k
Peter Hecht
Director5yrsUS$590.26k14.87%
$ 1.1m
Errol De Souza
Independent Chairman3yrsUS$58.53k1.18%
$ 91.2k
Harald H. H. Schmidt
Member of Scientific Advisory Board3.3yrsno datano data
Robert Malenka
Member of Scientific Advisory Board3.3yrsno datano data
Daniela Salvemini
Member of Scientific Advisory Board3.3yrsno datano data
Mark Currie
Chair of Scientific Advisory Boardno dataUS$366.78kno data
Andrew Budson
Member of Clinical Advisory Board3.3yrsno datano data
Eric Smith
Member of Clinical Advisory Board3.3yrsno datano data
M Westover
Member of Clinical Advisory Board3.3yrsno datano data
David Salat
Member of Clinical Advisory Board3.3yrsno datano data
Marni Falk
Member of Scientific Advisory Board3.3yrsno datano data

3.3yrs

Average Tenure

67.5yo

Average Age

Experienced Board: CYCN's board of directors are considered experienced (3.3 years average tenure).


Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.